Residual Mass After Lymphoma: — Scar or Active Disease?

Not at all — and this is one of the most important things to understand about lymphoma. A mass remaining on the scan after treatment is expected in many cases, particularly after bulky disease. What matters is whether that mass is metabolically active on PET, not whether it is visible on CT. If the PET shows no significant uptake — a complete metabolic response — the residual tissue is almost always inactive scar, and that is a successful treatment outcome.

A Deauville score describes the degree of residual metabolic activity in your scan relative to two reference points. What a particular score means for your situation — whether it changes your treatment, warrants a repeat scan, or requires a biopsy — depends on your cancer type, the treatment you received, and the full clinical picture. Your haemato-oncologist is the right person to interpret your score. A Deauville number without that context can be seriously misleading.

Shrinkage on CT alongside reduced or absent PET activity is generally a positive finding, and for many patients it is exactly what the treating team is hoping to see. A mass that is smaller and metabolically quiet fits the pattern of inactive scar. Whether partial size reduction is sufficient, or whether the team wants to see further change, depends on where the disease was, what your scan looked like before treatment, and what the Deauville score shows. Ask your team to walk you through the comparison between the two scans.

A biopsy is typically considered when the PET scan shows residual activity significant enough to suggest active disease may still be present, and when a change in treatment would follow a positive result. It is not done routinely after every scan that shows a residual mass. The decision weighs the likelihood that the finding is active lymphoma, the accessibility of the mass, and what would change in management if the result were positive. Your haemato-oncologist will explain the reasoning if a biopsy is being considered.

Relapse after a complete metabolic response is possible, though the risk varies by lymphoma type and stage. A negative PET at the end of treatment is a meaningful marker of response — but it is not a guarantee. This is why follow-up scans and clinical reviews continue after treatment ends. If you notice new symptoms between scheduled appointments — a new lump, unexplained fever, night sweats or weight loss — tell your team promptly rather than waiting for your next visit.

Fibrous scar tissue in lymphoma can persist on CT for years, sometimes permanently. This does not mean the lymphoma is still there. As long as the PET component of your scan shows no significant metabolic activity, the persistent mass on CT is what it appears to be: inactive tissue. Over time, some masses shrink further; others stay the same size indefinitely. Your follow-up schedule will be set by your team based on how long they want to monitor the pattern.